Adagene, which is on a quest to produce immunotherapies that don't attack healthy cells, is partnering with Sanofi for up to four "safe" antibody candidates in oncology. Sanofi will be able to apply Adagene's technology to two of its antibody candidates with the option to tack on two more down the road.